Pfizer inks $60M settlement to close Nurtec anti-kickback suit
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT. A Pfizer spokesperson said the company has...
View ArticleObesity startup Found drives weight loss with low-cost generic drugs over...
Found, a telehealth startup that treats obesity with medication and lifestyle coaching, unveiled new research showing tens of thousands of its patients lost significant amounts of weight through its...
View ArticlePharmacy middlemen lose bid to toss new Hawaii complaint
The state of Hawaii can proceed with a lawsuit against the three largest pharmacy benefit managers after it updated its complaint, a federal judge has ruled. Judge Leslie Kobayashi of the US District...
View ArticleSarepta shares two-year DMD data that may inform Europe decision
Sarepta Therapeutics unveiled new results from the second part of a clinical trial for its Duchenne muscular dystrophy gene therapy Elevidys, showing that patients who received the gene therapy...
View ArticleUpdated: Cell therapy biotech Affini-T Therapeutics reduces staff
Affini-T Therapeutics laid off an undisclosed number of employees last week, CEO Jak Knowles confirmed in a post-publication email to Endpoints News on Tuesday. The startup was coming up on a likely...
View ArticleVersant's fourth obesity biotech starts with $65M and a GIP antagonist
Another obesity biotech emerged on Tuesday morning, this time taking a different approach to the GIP antagonism story than Amgen and another startup called Antag Therapeutics. Helicore Biopharma broke...
View ArticleITM aims to compete with Novartis after Phase 3 radiopharma win
ITM Isotope Technologies Munich plans to seek approval for its β-emitting radioligand in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) following a Phase 3 success, the biotech said Tuesday....
View ArticleAtalanta gets $97M boost to take two siRNAs into clinic for rare neuro disorders
For five years, Atalanta Therapeutics operated with one investor. Now, F-Prime Capital is getting a bevy of financial support to propel two of the Boston biotech's RNAi drugs for rare neurological...
View ArticleLantheus to buy radiopharma player Evergreen Theragnostics for $250M upfront
In its latest move to expand its portfolio, Lantheus Holdings is spending $250 million upfront to buy radiopharma CDMO and diagnostics company Evergreen Theragnostics, which could also receive up to...
View ArticleAkero, 89bio disclose public offerings; BioAge drops Phase 2 obesity drug
Plus, news about Vigonvita Life Sciences and Lutris Pharma: For MASH developers, a race for cash: Akero Therapeutics aims to raise $300 million in an offering that was announced the same ...
View ArticleBiopharma execs split on RFK Jr. before confirmation hearing
Robert F. Kennedy Jr. will sit before a Senate committee on Wednesday and provide the first substantive glimpse into how he may run the nation's health department. Capitol Hill's questioning could...
View ArticleLeap Therapeutics treks toward pivotal study in colorectal cancer, drops...
Leap Therapeutics reported mixed results on Tuesday for an experimental treatment in gastric and colorectal cancer, announcing it is only moving forward with the latter indication. The biotech’s shares...
View ArticleWhat we know — and don’t know — about insurance denial rates
One insurance metric that we don’t often see showing up on earnings calls: the rate at which health plans issue denials. In the wake of UnitedHealthcare CEO Brian Thompson’s murder last month, a lot of...
View ArticleSemaglutide, tirzepatide compounder hit with FDA warning letter
Compounding facility ProRx Pharmacy Network has received an FDA warning letter over issues with its semaglutide and tirzepatide production. The FDA uncovered several issues at ProRx’s facility in...
View ArticleTwo February FDA adcomm meetings are delayed, canceled
President Donald Trump’s communications and travel freeze at HHS may be part of the reason an upcoming FDA advisory committee meeting has been delayed, and another one canceled. A Feb. 5 meeting on...
View ArticleOzempic label expanded to include reduced risk of worsening kidney disease
The FDA on Tuesday broadened the label of Novo Nordisk's blockbuster diabetes drug Ozempic. The GLP-1 injectable can now also be marketed for the reduction in risk of worsening kidney disease ...
View ArticleAstraZeneca, Daiichi Sankyo bring Enhertu to HER2-ultralow setting
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is now approved to treat a new subset of breast cancer patients with very low levels of HER2 protein. The blockbuster drug has been...
View ArticleLilly cuts mid-stage heart failure and chronic kidney drug
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to Endpoints News. The drug, an under-the-skin...
View ArticleJudge allows Aurion Biotech's path to IPO despite Alcon objections
A Delaware judge issued a split ruling in a bizarre legal squabble over the IPO plans of Aurion Biotech, which should allow the cell therapy startup to go ahead with its public offering. The judge' ...
View Article